A common variant of PPARgammaPro12Ala correlates with the clinical outcome of pancreatic cancer patients
Recently published genome-wide association studies (GWAS) have identified a number of common genetic variations associated with susceptibility to pancreatic ductal adenocarcinoma (PDAC), which can be mapped to core cancer signaling of PDAC. The peroxisome proliferator-activated receptor gamma (PPARgamma) signaling has been shown to be associated with various aspects of PDAC and a common variant of PPARgammaPro12Ala has been proposed as a novel risk allele. Thus, we aim to explore the clinical relevance of PPARgammaPro12Ala in a cohort of PDAC patients. In order to examine the frequency of PPARgammaPro12Ala in PDAC patients, pancreatic tissues from PDAC patients (506 patients retrieved from our tissue bank) were subjected to genomic DNA isolation and genotyped by high-resolution melting curve analysis and sequencing. In addition, the prevalence of the PPARgammaPro12Ala was correlated with clinical parameters of patients such as age, sex, tumor stage, grading and survival. In total, 27.6% of analyzed cases carried PPARgammaPro12Ala variant. The preliminary correlation analysis suggested that patients with PPARgammaPro12Ala had a tendence towards a shorter postoperative survival. Though the 1-year overall survival rate of PPARgammaPro12Ala was similar as the patients with wild-type PPARgamma, the 3- and 5-year overall survival rate is lower. Therefore, the further analysis in a large cohort of PDAC patients is warranted.